Core Viewpoint - The announcement details Mr. Cao Fei's tender offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a focus on the acquisition's timeline, purpose, and conditions [2][3][4]. Group 1: Tender Offer Details - The tender offer is valid from June 18, 2025, to July 17, 2025, with specific conditions regarding the withdrawal of acceptance in the last three trading days [2][6][9]. - Mr. Cao Fei intends to acquire 350,841,357 shares, representing 38.06% of the total share capital of the company, at a price of 26.93 yuan per share [5][6]. - The payment method for the tender offer will be in cash [4][5]. Group 2: Purpose of the Tender Offer - The tender offer is a result of a share transfer agreement between Mr. Cao Longxiang and Mr. Cao Fei, where 10.10% of Jiangsu Jichuan Holding Group Co., Ltd. was transferred to Mr. Cao Fei for 10.1 million yuan, indicating a family restructuring of shareholding [2][3]. - The acquisition aims to fulfill the legal obligation for a comprehensive tender offer, and it does not intend to terminate the listing status of Jichuan Pharmaceutical [3]. Group 3: Procedures for Acceptance - Shareholders can submit their acceptance of the tender offer through designated securities companies during the offer period, with specific codes for the tender offer [7][8]. - Accepted shares will be temporarily held by China Securities Depository and Clearing Corporation Limited during the offer period, and shareholders cannot transfer these shares until the withdrawal process is completed [8][10]. Group 4: Additional Information - The company will provide updates on the progress of the tender offer and will issue a results announcement after the offer period ends [6][13]. - Investors seeking detailed information can refer to the tender offer report published on June 16, 2025, on the Shanghai Stock Exchange website [15].

Group 1 - The actual controller of Jichuan Pharmaceutical, Cao Longxiang, is transferring shares to his son, Cao Fei, which triggers a mandatory tender offer for the company [1][2] - Cao Fei will acquire 351 million shares, representing 38.06% of the total issued shares, with a maximum transaction value of 9.448 billion yuan [1][2] - Following the share transfer, Cao Fei's stake in Jichuan Holdings will increase to 60%, allowing him to indirectly control 517 million shares of Jichuan Pharmaceutical, exceeding the 30% threshold for a mandatory tender offer [2] Group 2 - Jichuan Pharmaceutical is facing significant pressure, with revenue and net profit declining for four consecutive quarters due to price cuts from centralized procurement [4] - In 2024, the company expects to achieve revenue of 8.017 billion yuan, a year-on-year decrease of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [4] - The company's sales expenses are high at 2.954 billion yuan, accounting for 36.85% of total revenue, while R&D expenses are only 445 million yuan, representing 5.55% of total revenue [4]

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-044 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的第一次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生自 2025 年 6 月 18 日起要约收购公司股份 350,841,357 股。本次 要约收购的具体情况如下： 一、 本次要约收购的基本情况 1 本次公告为曹飞先生要约收购湖北济川药业股份有限公司（以下简称"上 市公司"或"公司"）股份的第一次提示性公告。 预受要约申报代码：706034，申报简称：济川收购 要约收购支付方式：现金 要约收购有效期：2025 年 6 月 18 日至 2025 年 7 月 17 日。按照本次要 约收购申报程序，本次要约收购期限届满前最后三个交易日（2025 年 7 月 15 日、2025 年 7 月 16 日、2025 年 7 月 17 日），预受股东不得撤回 其对要约的接受。 1.被收 ...

Group 1 - The core point of the news is the internal equity structure adjustment within the family of the actual controller of Jichuan Pharmaceutical, leading to a mandatory general offer for shares, initiated by Cao Fei, which does not aim to terminate the company's listing status [1] - The equity transfer involves Cao Longxiang transferring 10.10% of his shares in Jichuan Holdings to his son, Cao Fei, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of the listed company, accounting for 56.07% of the total share capital [1] - The mandatory general offer will cover all freely tradable shares held by other shareholders, totaling 351 million shares, which is 38.06% of the company's total share capital, with an offer price of 26.93 yuan per share, valid for 30 days from June 18, 2025, to July 17, 2025 [1][2] Group 2 - The total maximum funding required for the general offer is approximately 94.48 billion yuan, sourced from the acquirer's own funds and legally raised funds, with 18.95 billion yuan deposited as a performance guarantee [2] - The transition of control from one generation to the next is a significant trend in the industry, with over 80% of private enterprises in China being family-owned, and many are currently undergoing generational handovers [2] - The company aims to maintain stable development of its core business while promoting innovation and transformation, focusing on a dual pillar layout of traditional Chinese medicine and chemical medicine, and accelerating the launch of new products through strategic cooperation and technology introduction [3]

Core Viewpoint - The company has received a takeover offer from Mr. Cao Fei, which triggers a mandatory general offer due to the increase in shareholding above 30% [2][4]. Summary by Sections Offer Details - The offer price is set at 26.93 yuan per share, with a total of 350,841,357 shares being offered, representing 38.06% of the company's issued shares [4][5]. - The offer period lasts for 30 days, from June 18, 2025, to July 17, 2025, during which shareholders cannot withdraw their acceptance in the last three trading days [7]. Shareholding Changes - Mr. Cao Longxiang plans to transfer 10.10% of his shares in Jiangsu Jichuan Holding Group to his son, Mr. Cao Fei, making Mr. Cao Fei the controlling shareholder of Jichuan Holding with 60% ownership [2][4]. - Following the transfer, both Mr. Cao Fei and Mr. Cao Longxiang will be the joint actual controllers of the listed company, ensuring that the company's independence remains unaffected [2][4]. Financial Arrangements - The total maximum funding required for the offer is 18.95 billion yuan, with at least 20% of this amount deposited as a performance guarantee [6]. - The funding for the offer comes from the acquirer's own funds and legally raised funds, with no involvement from the listed company or its affiliates [6][7]. Compliance and Procedures - The acquirer, Mr. Cao Fei, does not require any authorization or approval from relevant institutions to make the offer [4]. - The offer is made in compliance with the Securities Law and the Takeover Management Measures, ensuring that the offer price is based on the weighted average price of the company's shares over the previous 30 trading days [5].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-042 湖北济川药业股份有限公司 关于收到要约收购报告书的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 2025 年 6 月 11 日，公司实际控制人曹龙祥先生与其子曹飞先生签署《江 苏济川控股集团有限公司股权转让协议》，曹龙祥先生拟将其所持江苏 济川控股集团有限公司（以下简称"济川控股"）10.10%的股权转让给 曹飞先生。本次股权转让完成后，曹飞先生持有济川控股 60%的股权， 成为济川控股的控股股东，并通过济川控股、西藏济川企业管理有限公 司（以下简称"西藏济川"）间接控制上市公司 516,757,360 股股份， 占上市公司总股本的 56.07%，超过上市公司已发行股份的 30%，从而 触发全面要约收购义务。 本次股权转让系公司实际控制人曹龙祥先生向其子曹飞先生转让部分 济川控股股权，属于实际控制人家族内部的股权结构调整行为，不会影 响公司的独立性，不会对公司经营产生重大影响。本次转让完成后，上 市公司控股股东不变， ...

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-043 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的申报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 湖北济川药业股份有限公司（以下简称"济川药业"或"公司"）于 2025 年 6 月 12 日收到曹飞先生(以下简称"收购人")发来的《湖北济川药业股份有 限公司要约收购报告书》(以下简称"《要约收购报告书》")等文件，就收购人 要约收购的有关事项作出申报公告如下: 一、 本次要约收购申报的有关事项 （一）要约收购的提示 《要约收购报告书》披露后 30 日内，本公司将在上海证券交易所网站 （http://www.sse.com.cn）发布 3 次要约收购提示性公告。 （二）要约收购情况 1 预受要约申报代码：706034 申报简称：济川收购 要约收购支付方式：现金 要约收购价格：26.93 元/股 要约收购数量：全面要约，拟收购股份数量为 350,841,357 股，占济川 药业总股份的比例为 38.06%。 要约收购有效期 ...

证券简称：济川药业 证券代码：600566.SH 湖北济川药业股份有限公司 要约收购报告书 | 上市公司名称： | 湖北济川药业股份有限公司 | | --- | --- | | 股票上市地点： | 上海证券交易所 | | 股票简称： | 济川药业 | | 股票代码： | 600566.SH | | 收购人： 曹飞 | | | --- | --- | | 住所 ： | 上海市黄浦区**** | | 一致行动人： 曹龙祥 | | | 住所 ： | 江苏省泰兴市**** | | 一致行动人： | 江苏济川控股集团有限公司 | | 住所 ： | 泰兴市黄桥工业园区兴业标房 号厂房内 1 | | 一致行动人： | 西藏济川企业管理有限公司 | | 住所 ： | 拉萨经济技术开发区大连路以西、格桑路以北总部 | | | 经济基地 B（栋）3 单元 4 层 404 号 | 收购方财务顾问： 签署日期：二零二五年六月 湖北济川药业股份有限公司 要约收购报告书 特别提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具 有相同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占 ...

北京植德律师事务所 关于 《湖北济川药业股份有限公司要约收购报告书》的 法律意见书 植德(证)字[2025]0024-1 号 | 释 人 | | --- | | 一、收购人及其一致行动人的基本情况 | | 二、要约收购的目的 . | | 三、要约收购方案 . | | 四、收购资金来源 . | | 五、后续计划 . | | 六、对上市公司的影响分析 . | | 七、与上市公司之间的重大交易 . | | 八、前六个月内买卖上市公司股份的情况 . | | 九、《要约收购报告书》的格式与内容 | | 十、参与本次要约收购的专业机构 | | 十一、结论意见 | l 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 济川药业、公司、上市公司 | 분 | 湖北济川药业股份有限公司 | | --- | --- | --- | | 收购人 | 블 | ■ K | | 济川控股 | 指 | 江苏济川控股集团有限公司 | | 西藏济川 | 指 | 西藏济川企业管理有限公司 | | 一致行动人 | 指 | 曹龙祥、济川控股、西藏济川 | | 本次股权转让/本次转让 | 指 | 曹龙祥将其持有的济川控股10. ...

曹飞 要约收购 北京博星证券投资顾问有限公司 关于 湖北济川药业股份有限公司 之 财务顾问报告 二〇二五年六月 北京博星证券投资顾问有限公司 财务顾问报告 重要提示 本部分所述的词语或简称与本报告书"释义"部分所定义的词语或简称具有相 同的含义。 1、本次股权转让前，济川控股持有上市公司 416,757,360 股股份（占上市公司 总股本的 45.22%），为上市公司控股股东，曹龙祥持有济川控股 50.10%股权为其 控股股东，曹飞持有济川控股 49.90%股权；西藏济川为济川控股全资子公司，持有 上市公司 100,000,000 股股份（占上市公司总股本的 10.85%）；曹龙祥持有上市公 司 46,838,458 股股份（占上市公司总股本的 5.08%）。本次股权转让前，上市公司 实际控制人为曹龙祥，曹龙祥与收购人曹飞系父子关系。 2025 年 6 月 11 日，曹龙祥与曹飞签署《股权转让协议》，曹龙祥将其持有的 济川控股 10.10%股权以 1,010 万元价格转让给曹飞，股权转让完成后，曹飞持有济 川控股 60%股权，为济川控股控股股东，并通过济川控股、西藏济川间接控制上市 公司 516,757,36 ...